Navigation Links
ADVENTRX to Present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on November 11
Date:11/4/2010

SAN DIEGO, Nov. 4, 2010 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Wall Street Analyst Forum 21st Annual Institutional Investor Conference on Thursday, November 11, 2010 at 12:50 p.m. Eastern time, at The University Club in New York City.

Interested parties can access a live audio webcast and slide presentation on the Company's web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use.  More information can be found on the Company's web site at www.adventrx.com.


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ADVENTRX Submits Exelbine™ New Drug Application
2. ADVENTRX to Participate in Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
3. Reminder: ADVENTRX Presents Today at the Lippert/Heilshorn Life Sciences & MedTech Virtual Conference
4. ADVENTRX Announces 9-Month Stability Data Results for ANX-530
5. ADVENTRX Added to Russell Microcap Index
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17
7. ADVENTRX Pharmaceuticals Announces Closing of Financing
8. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
10. ADVENTRX Receives Brand Name Acceptance for ANX-530
11. ADVENTRX Receives Refuse to File Letter from FDA on ANX-530 New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
(Date:3/27/2017)... 2017  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical ... diseases in children, today reported financial results for ... 31, 2016 and provided an update on its ... make progress during the fourth quarter of 2016 ... primate safety study, and with our lead development ...
(Date:3/24/2017)... Research and Markets has announced the ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report ... cell therapy manufacturing and focuses both on contract manufacturers and ... anticipated to emerge as viable alternatives to conventional treatment options. ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... it will co-exhibit with technology partners LG Business Solutions at ATARC Federal ... Center in Washington D.C., will provide education and examination into the mobility tools ...
(Date:3/27/2017)... ... March 27, 2017 , ... American Veterinarian™, ... coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a business ... the April edition of American Veterinarian™. , “We look forward to ...
(Date:3/27/2017)... ... March 27, 2017 , ... Kwalu, a leading provider ... a row; they are the recipient of the prestigious “Best Overall Design Strategy ... award at Design Connections 2017. Top A&D professionals from leading firms, furniture manufacturers ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... testing methods are complicated and require expert user knowledge. In a live webinar ... dedicated to the simplified, yet highly accurate, determination of sodium. , It has ...
(Date:3/27/2017)... Fla. (PRWEB) , ... March 27, 2017 , ... The ... and the number of homeowners utilizing DIY and unlicensed contractors for renovations is also ... remodel or replacement project in 2015, and of those, 42% failed to use a ...
Breaking Medicine News(10 mins):